Alfasigma

Privately held: no public share price

Assets

(2 total)
2Total Assets
1Approved
1Phase 3 / Filed
0Phase 1–2 / Early
2Diseases
Quick filter:
Showing 2 of 2 assets
Target & Modality
Approved
Rifamycin AntibacterialSmall molecule
Travelers' Diarrhea
filgotinib(Jyseleca)
Phase 3
JAK · JAK1Small molecule
Rheumatoid Arthritis

Upcoming events

(3 total)

Estimated primary-completion dates from ClinicalTrials.gov and expected earnings reports. These are registry estimates, never confirmed readout dates; they can move as trials progress.

Add these trial readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.

2027 (2)
June 2027 (1)
filgotinib · JyselecaPhase 3Polyarticular Course Juvenile Idiopathic Arthritis
Est. primary completion 2027-06 · NCT07554495 · CT.gov ↗
What to watch
December 2027 (1)
filgotinib · JyselecaPhase 3Juvenile Idiopathic Arthritis (JIA)
Est. primary completion 2027-12 · NCT07553182 · CT.gov ↗
What to watch
2028 (1)
June 2028 (1)
filgotinib · JyselecaPhase 3Ulcerative Colitis
Est. primary completion 2028-06 · NCT06865417 · CT.gov ↗
What to watch

See the full readout calendar ↗

Financial reports

No financial reports recorded.